8 August 2016 - Takeda Canada receives approval for Ninlaro (ixazomib) - the first and only oral proteasome inhibitor providing a new disease management option for adult patients living with incurable cancer.

Takeda Canada has received approval from Health Canada for Ninlaro (ixazomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Ninlaro is the first and only oral proteasome inhibitor, and the approval makes a new option available to meet the urgent needs of patients living with relapsed and/or refractory multiple myeloma, a devastating, rare, relapsing and incurable cancer.

Read Takeda press release